SHIELD HD is an International study that will follow a group of people over time who have or are at risk of developing Huntington´s Disease. SHIELD HD will collect health information that includes medical history, blood and cerebrospinal fluid samples. Participants will also undergo MRIs, cognitive and motor function tests. The information will be used to evaluate the natural history of HD and its biomarkers that are associated with the modulation of the number of CAG (cytosine-adenine-guanine) repeats in the mutant Huntingtin (mHTT) gene. The results of this study will inform assessments for a future interventional treatment trial.
This international study will follow a group of people over time who have or are at risk of developing HD. Health information will be collected including medical history, blood and CSF samples. Participants will also undergo MRIs, cognitive and motor function tests. The information will be used to look at the natural history of HD and its biomarkers that are linked with changes in the CAG repeat.